StreetAlpha.app
Home › Stocks › IVVD

Invivyd, Inc. (IVVD)

Healthcare
$0.41
▼ −7.45%
LAST CLOSE · NOV 20

Invivyd develops antibody therapies to prevent and treat serious viral infections, starting with COVID-19. It last closed at $0.41 on Nov 20, down 7.45% on the day. The next earnings report for IVVD is expected around Thu, Mar 4, 2027. For the quarter ended Sep 2026, IVVD reported EPS of -$0.10 on revenue of $15.4M, with revenue up 17.7% from a year ago. Over its last 8 reports the stock moved an average of 8.6% the session after earnings. Over the last 12 months IVVD insiders bought $0 of stock on the open market and sold $532K, according to SEC Form 4 filings.

AI Auto Pilots
Is IVVD in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold IVVD.

Key Stats

Last 12 months
Results
Revenue
$60.7M
+21.3% vs a year ago
Net income
−$130.3M
−214.8% margin
EPS (diluted)
−$0.38
Free cash flow
−$134.1M
−221.0% margin
Valuation
Market cap
$122.0M
295.6M shares
P/E
–
No P/E while losing money
Price to sales
2.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$126.4M
At Sep 30
Shareholder equity
$150.5M
Shares outstanding
295.6M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $0$0FY2023FY2024: $25.4M$25.4MFY2024FY2025: $53.4M$53.4MFY2025

From IVVD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
Mar 4
Estimated date · Time not announced
Reported EPS
-$0.10
Quarter ended Sep 2026
Year ago EPS
-$0.06
Same quarter last year
Revenue
$15.4M
+17.7% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.15Dec '24Mar 2025: -$0.14Mar '25Jun 2025: -$0.12Jun '25Sep 2025: -$0.06Sep '25Dec 2025: $0.00Dec '25Mar 2026: -$0.13Mar '26Jun 2026: -$0.14Jun '26Sep 2026: -$0.10Sep '26Latest -$0.10
Revenue by quarter
Dec 2024: $13.8MDec '24Mar 2025: $11.3MMar '25Jun 2025: $11.8MJun '25Sep 2025: $13.1MSep '25Dec 2025: $17.2MDec '25Mar 2026: $13.7MMar '26Jun 2026: $14.3MJun '26Sep 2026: $15.4MSep '26Latest $15.4M
How IVVD moved after its last 8 reports
Average move the session after a report ±8.6%
Nov 16, 2026Time not announced−7.6%
Aug 13, 2026After the close+5.1%
May 14, 2026Time not announced−21.1%
Mar 5, 2026Time not announced+1.8%
Jan 8, 2026Time not announced+4.6%
Nov 6, 2025Time not announced+1.3%
Aug 14, 2025After the close−11.5%
May 15, 2025Time not announced−15.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on IVVDStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on IVVD
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on IVVD

Technical Analysis

IVVD · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 36% below its 20 day and 67% below its 50 day average. It is 155% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the 52 week low at $0.41, and the nearest resistance the Pivot at $0.43.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 14.2%/day
Key levels
$3.0152 week high+634.1%
$1.05200 day average+156.1%
$0.73100 day average+78.0%
$0.6950 day average+68.3%
$0.64Swing high (Oct 29)+56.1%
$0.5620 day average+36.6%
$0.45Pivot R1+9.8%
$0.43Pivot+4.9%
$0.4152 week low+0.0%
$0.41Last close
$0.39Pivot S1−4.9%
Indicators
RSI (14)27.60Oversold below 30Oversold
MACD-0.06Below its signal lineBearish
Stochastic2.0Near the bottom of its rangeOversold
ADX (14)24.0Weak trend
Williams %R-100.0Oversold below −80, overbought above −20Oversold
CCI (20)-237.6Oversold below −100, overbought above 100Oversold
Rate of change−26.7%Change over 10 sessionsBearish
ATR (14)$0.06Typical daily range, 14.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IVVD

What happened before

See how IVVD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow IVVD usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How IVVD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for IVVDHow many large options trades hit IVVD, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

IVVD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲72 buying vs 48 selling
  • ▼Held by funds -4.9 pts
  • ▲Funds holding +10
  • ▼Superinvestors: 0 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding136126+7.9%
In funds' top 10110.0%
Held by funds74.0%78.8%−4.9 pts
New / increased27 / 4534 / 380.0%
Reduced / sold out31 / 1726 / 46−33.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IVVD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

IVVD Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$532K10 sales · 5 insiders
100% of the selling was under pre-arranged trading plans.
2026-02 sold $355K2026-08 sold $177KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 18Robert D. Allen IIIChief Scientific OfficerSale plan37,722$0.78$29K
Aug 18Jill AndersenChief Legal Officer, SecretarySale plan67,962$0.78$53K
Aug 18William E. DukeCFOSale plan40,780$0.78$32K
Aug 18Julie GreenChief Human Resources OfficerSale plan40,780$0.78$32K
Aug 18Timothy Edward LeeChief Commercial OfficerSale plan40,780$0.78$32K
Feb 18Jill AndersenChief Legal Officer, SecretarySale plan67,710$1.56$106K
Every insider buy and sale for IVVD over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See IVVD insider trades →

From SEC Form 4 filings by IVVD's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IVVD is in one of them and how their past IVVD trades turned out.

IVVD in the AI portfolios
Loading…

IVVD News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IVVD in an article yet. Here's the latest on the wider market.

IVVD in the news

About Invivyd

Invivyd is a biopharmaceutical company based in New Haven, Connecticut, that develops antibody therapies for serious viral infectious diseases. Its first authorized product, PEMGARDA, is an antibody used to help prevent COVID-19 in people who are immunocompromised and unlikely to respond well to vaccination. The company is also developing next generation COVID-19 antibodies and early candidates for diseases such as RSV and measles. Its customers are mainly patients and the healthcare providers who treat them.

Headquarters
New Haven, CT